Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
November 2nd, 2014
13.9K views
We describe a non-invasive animal imaging platform that allows the detection, quantification, and monitoring of ovarian cancer growth and recurrence. This intra-peritoneal xenograft model mimics the clinical profile of patients with ovarian cancer.
Overview
This study presents a non-invasive imaging platform for monitoring ovarian cancer growth and recurrence in a xenograft model. The model closely mimics the clinical profile of ovarian cancer patients, allowing for real-time assessment of tumor progression and treatment response.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Animal Imaging
Background
- Ovarian cancer is a significant health concern with high recurrence rates.
- Existing models often require sacrificing animals for tumor assessment.
- Non-invasive imaging techniques can enhance the study of tumor biology and therapy responses.
- This study utilizes a xenograft model to replicate human ovarian cancer characteristics.
Purpose of Study
- To establish a non-invasive model for monitoring ovarian cancer.
- To evaluate tumor progression and response to therapies in real-time.
- To facilitate the identification of novel treatments for recurrent ovarian cancer.
Methods Used
- Injection of mCherry-labeled ovarian cancer stem cells into the uterine horn of nude mice.
- Real-time monitoring of tumor growth through fluorescence imaging.
- Use of a multimodal imaging system for comprehensive analysis.
- Calibration and positioning of mice for optimal imaging results.
Main Results
- The model successfully mimics the clinical profile of ovarian cancer.
- Real-time imaging allows for assessment of tumor burden without sacrificing animals.
- Fluorescence imaging correlates well with actual tumor size and progression.
- Data supports the evaluation of treatment responses and recurrence monitoring.
Conclusions
- The established model is a valuable tool for studying ovarian cancer.
- It enables the exploration of therapeutic strategies for recurrent cases.
- This approach enhances our understanding of tumor dynamics in vivo.
Frequently Asked Questions
What is the significance of using a xenograft model?
Xenograft models closely mimic human cancer biology, allowing for more relevant preclinical studies.
How does the imaging platform work?
The platform uses fluorescence imaging to monitor tumor growth and response to treatment in real-time.
What are the advantages of non-invasive monitoring?
Non-invasive methods reduce animal suffering and allow for repeated measurements over time.
Can this model be used for other types of cancer?
While this study focuses on ovarian cancer, the methodology may be adapted for other cancers.
What is the role of mCherry in this study?
mCherry is a fluorescent marker used to visualize and quantify tumor growth in the model.
How do researchers ensure the accuracy of tumor measurements?
Researchers calibrate the imaging system and validate findings with actual tumor burden assessments.
Executive Industry Relevance
This non-invasive imaging platform addresses a critical gap in ovarian cancer drug development by enabling longitudinal monitoring of intraperitoneal tumor burden without terminal endpoints. The model supports mechanistic de-risking of therapeutic candidates by providing quantitative, real-time fluorescence readouts that correlate with tumor progression and recurrence. This capability enhances predictive confidence in preclinical evaluation, particularly for therapies targeting chemoresistant disease, and informs go/no-go decisions earlier in the discovery pipeline.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses in a clinically relevant intraperitoneal ovarian cancer model that recapitulates patient disease progression.
- Operational Value: Supports biological de-risking through real-time, non-invasive monitoring of tumor burden as a surrogate for target engagement and pathway modulation.
- Predictive Value: Facilitates portfolio triage by allowing longitudinal assessment of treatment efficacy and recurrence dynamics in vivo.
Screening & Assay Development
- Assay Readiness: Prepares validated biological systems for downstream compound evaluation by establishing reproducible tumor establishment and imaging protocols.
- Quantitative Outputs: Generates fluorescence-based measurements that enable standardized, quantitative comparison of tumor growth across treatment groups.
- Platform Reuse: The multimodal rotation imaging system supports scalable, repeated imaging sessions, enhancing assay standardization and cross-experiment consistency.
Translational & Preclinical Research
- Disease Relevance: The intraperitoneal xenograft model closely mimics the clinical profile of ovarian cancer patients, supporting translational continuity from discovery to preclinical validation.
- Risk-Adjusted Advancement: Enables monitoring of tumor recurrence after therapy discontinuation, informing decisions on therapeutic durability and resistance mechanisms.
- Mechanistic De-risking: Provides predictive value by linking imaging readouts to actual tumor burden, reducing ambiguity in target validation and mechanism of action studies.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from early target validation through lead identification and preclinical efficacy testing, particularly for ovarian cancer therapeutics requiring intraperitoneal disease modeling.
- Discovery Biology: Supports hypothesis testing and pathway clarification by enabling non-invasive, longitudinal monitoring of tumor progression in a clinically relevant model.
- Screening: Enhances assay readiness through standardized tumor establishment and reproducible imaging workflows that support reliable compound evaluation.
- Analytics: Delivers quantitative fluorescence measurements and multimodal imaging outputs (fluorescence/X-ray co-registration) that allow teams to compare tumor burden across conditions and timepoints.
- Translational Research: Connects discovery findings to preclinical continuity by modeling intraperitoneal disease progression and recurrence, aligning with clinical disease patterns.
- Enterprise Reuse: The imaging platform and xenograft model constitute a reusable capability for multiple oncology programs, reducing redundant model development and enhancing throughput.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target validation by reducing mechanistic ambiguity through direct, real-time tumor monitoring.
- Operational Value: Improves standardization and reproducibility via calibrated imaging protocols and rotation-based 360-degree tumor detection.
- Strategic Value: Supports better go/no-go decisions by enabling early detection of recurrence and therapy response, reducing late-stage biological risk.
- Portfolio Impact: Enables risk-adjusted prioritization of therapeutic candidates based on longitudinal efficacy and recurrence data.
Implementation Considerations
- Requires expertise in murine surgical techniques, including intrauterine injection and peritoneal closure.
- Dependent on multimodal imaging infrastructure with fluorescence and X-ray capabilities, including a rotational imaging system.
- Necessitates cross-team standardization of imaging protocols, including angle ranges, increments, and session file management.
- Adaptation considerations include species-specific anatomical variations when extending the model to other preclinical systems.
- Practical limitations include the need for anesthesia during imaging sessions and potential signal attenuation at certain tumor orientations, mitigated by rotational acquisition.
Biopharma FAQs
Why does fluorescence quantification matter for target validation in ovarian cancer models?
Fluorescence quantification serves as a surrogate for tumor burden, enabling real-time assessment of target engagement and therapeutic efficacy without sacrificing animals. This supports mechanistic de-risking by providing longitudinal data on tumor progression and recurrence in a clinically relevant intraperitoneal model.
How does isolation of the uterine horn as an injection site support discovery pipeline goals?
Precise injection into the uterine horn ensures reliable establishment of intraperitoneal ovarian cancer xenografts that mimic clinical disease progression. This reproducibility supports consistent tumor modeling across studies, enabling reliable hypothesis testing and target validation in early discovery.
What do quantitative fluorescence and X-ray co-registration measurements enable in therapeutic evaluation?
These measurements enable anatomical localization of tumor signals and accurate quantification of intraperitoneal tumor burden across multiple angular positions. This improves detection sensitivity and supports reliable comparison of treatment effects, including recurrence monitoring after therapy discontinuation.
Why are replication requirements important for cross-functional collaboration in ovarian cancer model studies?
Replication through standardized rotation protocols and session file sharing ensures consistent imaging results across operators and timepoints. This supports reliable data sharing between discovery, preclinical, and translational teams, enhancing confidence in model reproducibility and therapeutic outcome assessments.
What statistical analysis capabilities are required before implementing the multimodal rotation imaging system?
Implementation requires the ability to correlate fluorescence signal intensity with actual tumor burden and assess signal variation across rotational angles. Statistical validation of imaging accuracy against endpoint tumor measurements is necessary to ensure reliable quantitative outputs for therapeutic decision-making.
